Page 24 - 2017 V1 InsideOut

XYNTHA® Antihemophilic Factor (Recombinant) Is Available as a SOLOFUSE Device or Rapid Reconstitution (R2) Kit
XYNTHA SOLOFUSE can change the way your patients experience reconstitution
Pre lled with XYNTHA and diluent, XYNTHA SOLOFUSE eliminates the transfer step and the vials for all-in-one reconstitution.1
XYNTHA R2 Kit
The R2 Kit comes with a low 4 mL diluent volume, pre lled syringe, needleless transfer system, and distinct vial adapter.3 The R2
Kit is available in 4 vial sizes: 250 IU, 500 IU, 1000 IU, and 2000 IU.3
250 IU
500 IU
1000 IU
2000 IU
3000 IU
SELECTED SAFETY INFORMATION FOR XYNTHA
• Donotuseinpatientswhohavemanifestedlife-threateningimmediatehypersensitivityreactions, including anaphylaxis, to the product or its components, including hamster proteins.
• Allergic-typehypersensitivityreactions,includinganaphylaxis,arepossiblewithXYNTHA.Inform patients of the early signs or symptoms of hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, and hypotension) and anaphylaxis. Discontinue XYNTHA if hypersensitivity symptoms occur and administer appropriate emergency treatment. XYNTHA contains trace amounts of hamster proteins. Patients may develop hypersensitivity to these proteins.
Please see Brief Summary on the last page of this advertisement.
References: 1. XYNTHA® SOLOFUSE® Antihemophilic Factor (Recombinant) Prescribing Information. Wyeth Pharmaceuticals Inc; 2014. 2. Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, e cacy, and pharmacokinetic equivalences to full-length recombinant factor VIII. Haemophilia. 2009;15(4)869-880. 3. XYNTHA® Antihemophilic Factor (Recombinant) Prescribing Information. Wyeth Pharmaceuticals Inc; 2014.